TY - JOUR
T1 - A paradigm shift in cancer nanomedicine
T2 - from traditional tumor targeting to leveraging the immune system
AU - Sofias, Alexandros Marios
AU - Combes, Francis
AU - Koschmieder, Steffen
AU - Storm, Gert
AU - Lammers, Twan
N1 - Funding Information:
S.K. reports research funding from Novartis, Janssen, AOP Orphan Pharmaceuticals AG, and Bristol-Myers Squibb as well as consultancy honoraria from Novartis, Incyte/Ariad, Bristol-Myers Squibb, AOP Orphan Pharmaceuticals AG, Pfizer, Celgene, Bayer, Roche, CTI, and Shire. T.L. reports research funding and consultancy honoraria from Cristal Therapeutics.The authors gratefully acknowledge financial support by the European Research Council (ERC: Meta-Targeting (864121)), the European Union (European Fund for Regional Development: TAKTIRA (EFRE-0801767), the German Research Foundation (DFG: SFB/TRR57, SFB1066, GRK/RTG 2375 (Tumor-targeted Drug Delivery; Project number: 331065168), KO 2155/6-1 and KO 2155/7-1), and the German Federal Ministry of Education and Research (BMBF: PP-TNBC, Project number: 16GW0319K).
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/6
Y1 - 2021/6
N2 - Twenty-five years after the approval of the first anticancer nanodrug, we have to start re(de)fining tumor-targeted drug delivery alongside advances in immuno-oncology. Given that cancer is characterized by an immunological imbalance that goes beyond the primary tumor, we should focus on targeting, engaging, and modulating cancer-associated immune cells in the tumor microenvironment (TME), circulation, and immune cell-enriched tissues. When designed and applied rationally, nanomedicines will assist in restoring the immunological equilibrium at the whole-body level, which holds potential not only for cancer therapy, but also for the treatment of a range of other disorders.
AB - Twenty-five years after the approval of the first anticancer nanodrug, we have to start re(de)fining tumor-targeted drug delivery alongside advances in immuno-oncology. Given that cancer is characterized by an immunological imbalance that goes beyond the primary tumor, we should focus on targeting, engaging, and modulating cancer-associated immune cells in the tumor microenvironment (TME), circulation, and immune cell-enriched tissues. When designed and applied rationally, nanomedicines will assist in restoring the immunological equilibrium at the whole-body level, which holds potential not only for cancer therapy, but also for the treatment of a range of other disorders.
UR - http://www.scopus.com/inward/record.url?scp=85103506385&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2021.02.017
DO - 10.1016/j.drudis.2021.02.017
M3 - Review article
C2 - 33617793
AN - SCOPUS:85103506385
SN - 1359-6446
VL - 26
SP - 1482
EP - 1489
JO - Drug discovery today
JF - Drug discovery today
IS - 6
ER -
